Home / Resource Library / Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from FOLL12 Phase III Trial of the Fondazione Italiana Linfomi
Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from FOLL12 Phase III Trial of the Fondazione Italiana Linfomi